Skip to Content
Merck
CN

Key Documents

View All Documentation

EHU072651

MISSION® esiRNA

targeting human NAV3 (2)

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.51
UNSPSC Code:
41105324
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

description

Powered by Eupheria Biotech

Quality Level

100

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

CCACTAGCCTTGGTCTGAGCTCTGACTGCATTGCTAGCTACTGTATAGGAGACTTAATTAGATCCCATAACCTAGAAGTGCCTGAATTGCTGCCTTGTGGATACCTTGTTGGAGATAATAACATCATCACTGTGAACCTCAAAGGGGTAGAAGAAAATAGTTTGGACAGTTTTGTTTTTGATACGCTGATTCCTAAACCAATTACCCAAAGGTACTTTAACTTGTTGATGGAGCATCACAGAATTATACTCTCAGGACCGAGTGGTACTGGAAAGACCTATTTGGCAAACAAACTTGCTGAATATGTAATAACCAAATCTGGAAGGAAAAAAACAGAGGATGCAATTGCCACTTTTAATGTGGACCACAAGTCAAGTAAGGAATTGCAACAATATCTAGCTAACCTGGCTGAACAGTGCAGTGCTGATAATAATGGAGTGGAGCTCCCAG

Ensembl | human accession no.

ENSG00000067798

NCBI accession no.

NM_014903

shipped in

ambient

storage temp.

−20°C

Gene Information

human ... NAV3(89795)

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ryan Charles Pink et al.
Gynecologic oncology, 137(1), 143-151 (2015-01-13)
Ovarian cancer is the deadliest gynaecological cancer. A major contributor to the poor survival rate is the development of chemoresistance to platinum-based therapies such as cisplatin and carboplatin. Here we aimed to test the role of miRNAs in the acquisition

Global Trade Item Number

SKUGTIN
EHU072651-20UG04061828612017
EHU072651-50UG04061828372522